ArticlePloS one2019
"Age matters"-German claims data indicate disparities in lung cancer care between elderly and young patients.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Epidemiology of cancer in older adults: a systematic review of age-related differences in solid malignancies treatment.Current oncology reports · 2025Pooled it
- Sleep trajectory of hospitalized medically ill older adults: do sleep medications make a difference?Sleep · 2025Article
- Age differences in the treatment of lung cancer-a cohort study among 42,000 patients from Germany.Journal of cancer research and clinical oncology · 2024Article
- Multiomics-Based Feature Extraction and Selection for the Prediction of Lung Cancer Survival.International journal of molecular sciences · 2024Article
- Pulmonary Diseases in Older Patients: Understanding and Addressing the Challenges.Geriatrics (Basel, Switzerland) · 2024Article
- Access to cancer clinical trials for racialised older adults: an equity-focused rapid scoping review protocol.BMJ open · 2024Article
- Impact of lung cancer screening with low-dose chest computed tomography on an older population: a retrospective cohort study.Translational lung cancer research · 2023Article
- Deep learning to estimate lung disease mortality from chest radiographs.Nature communications · 2023Article
- Sociodemographic Survival Disparities for Lung Cancer in the United States, 2000-2016.Journal of the National Cancer Institute · 2022Article
- Is immunotherapy at reduced dose and radiotherapy for older patients with locally advanced non-small lung cancer feasible?-a narrative review by the international geriatric radiotherapy group.Translational cancer research · 2022Review
- Use of algorithms for identifying patients in a German claims database: learnings from a lung cancer case.BMC health services research · 2022Observational
- Development of a patient-oriented navigation model for patients with lung cancer and stroke in Germany.BMC health services research · 2022Article
- Article
- All-Cause and Cancer-Specific Death of Older Adults Following Surgery for Cancer.JAMA surgery · 2021Article
- Excess mortality and undertreatment in elderly lung cancer patients: treatment nihilism in the modern era?ERJ open research · 2021Article
- Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation.Thoracic cancer · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough lung cancer is most commonly diagnosed in elderly patients, evidence about tumor-directed therapy in elderly patients is sparse, and it is unclear to what extent this affects treatment and care. Our study aimed to discover potential disparities in care between elderly patients and those under 65 years of age.
methodsWe studied claims from 13 283 German patients diagnosed with lung cancer in 2009 who survived for at least 90 days after diagnosis. We classified patients as "non-elderly" (≤ 65), "young-old" (65-74), "middle-old" (75-84), and "old-old" (≥ 85). We compared receipt of tumor-directed therapy (6 months after diagnosis), palliative care, opioids, antidepressants, and pathologic diagnosis confirmation via logistic regression. We used generalized linear regression (gamma distribution) to compare group-specific costs of care for 3 months after diagnosis. We adjusted all models by age, nursing home residency, nursing care need, comorbidity burden, and area of residence (urban, rural). The age group "non-elderly" served as reference group.
resultsCompared with the reference group "non-elderly", the likelihood of receiving any tumor-directed treatment was significantly lower in all age groups with a decreasing gradient with advancing age. Elderly lung cancer patients received significantly fewer resections and radiotherapy than non-elderly patients. In particular, treatment with antineoplastic therapy declined with increasing age ("young-old" (OR = 0.76, CI = [0.70,0.83]), "middle-old" (OR = 0.45, CI = [0.36,0.50]), and "old-old" (OR = 0.13, CI = [0.10,0.17])). Patients in all age groups were less likely to receive structured palliative care than "non-elderly" ("young-old" (OR = 0.84, CI = [0.76,0.92]), "middle-old" (OR = 0.71, CI = [0.63,0.79]), and "old-old" (OR = 0.57, CI = [0.44,0.73])). Moreover, increased age was significantly associated with reduced quotas for outpatient treatment with opioids and antidepressants. Costs of care decreased significantly with increasing age.
conclusionThis study suggests the existence of age-dependent care disparities in lung cancer patients, where elderly patients are at risk of potential undertreatment. To support equal access to care, adjustments to public health policies seem to be urgently required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.